Sigilon Therapeutics (SGTX) Income Statement (2020 - 2023)
Income Statement report data from Dec 31, 2020 to Jun 30, 2023 for Sigilon Therapeutics (SGTX).
Reported currency: USD
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||
Total Revenue | 5.90M (+21.40%) | 4.86M (+84.09%) | 2.64M (-37.88%) | 4.25M (+47.57%) | 2.88M (-9.15%) | 3.17M (+59.30%) | 1.99M (+2.05%) | 1.95M (-27.78%) | 2.70M (-8.78%) | 2.96M (-21.28%) | 3.76M |
Gross Profit | 5.90M (+21.40%) | 4.86M (+84.09%) | 2.64M (-37.88%) | 4.25M (+47.57%) | 2.88M (-9.15%) | 3.17M (+59.30%) | 1.99M (+2.05%) | 1.95M (-27.78%) | 2.70M (-8.78%) | 2.96M (-21.28%) | 3.76M |
Operating Expenses | |||||||||||
Research And Development | 7.45M (-4.24%) | 7.78M (+32.76%) | 5.86M (-29.23%) | 8.28M (-30.30%) | 12M (+2.24%) | 12M (-20.90%) | 15M (-11.77%) | 17M (-6.20%) | 18M (+11.01%) | 16M (+11.51%) | 14M |
Selling General And Administrative | 5.88M (+36.11%) | 4.32M (-4.42%) | 4.52M (+2.96%) | 4.39M (-12.90%) | 5.04M (+0.40%) | 5.02M (+9.37%) | 4.59M (-8.93%) | 5.04M (+1.00%) | 4.99M (-9.93%) | 5.54M (+57.83%) | 3.51M |
Operating Expenses | 13M (+10.16%) | 12M (+16.78%) | 10M (-18.22%) | 13M (-25.06%) | 17M (+1.68%) | 17M (-13.69%) | 19M (-11.11%) | 22M (-4.62%) | 23M (+5.62%) | 22M (+20.68%) | 18M |
Operating Income | |||||||||||
Operating Income | -7.43M (+2.48%) | -7.25M (-6.21%) | -7.73M (-8.19%) | -8.42M (-40.03%) | -14.04M (+4.15%) | -13.48M (-22.04%) | -17.29M (-12.41%) | -19.74M (-1.50%) | -20.04M (+7.92%) | -18.57M (+31.80%) | -14.09M |
EBITDA | -7.12M (+2.74%) | -6.93M (-6.48%) | -7.41M (-12.00%) | -8.42M (-38.63%) | -13.72M (+4.26%) | -13.16M (-22.54%) | -16.99M (-12.56%) | -19.43M (-1.77%) | -19.78M (+7.97%) | -18.32M (+32.18%) | -13.86M |
Other Income / Expenses | |||||||||||
Interest Income | 430K (-10.42%) | 480K (+20.00%) | 400K (+33.33%) | 300K (+66.67%) | 180K (+200.00%) | 60K (+20.00%) | 50K (-16.67%) | 60K (-14.29%) | 70K (-22.22%) | 90K (+125.00%) | 40K |
Interest Expense | -310.00K (-49.18%) | -610.00K (-6.15%) | -650.00K (+6.56%) | -610.00K (+12.96%) | -540.00K (+10.20%) | -490.00K (-3.92%) | -510.00K (+2.00%) | -500.00K (+2.04%) | -490.00K (0.00%) | -490.00K (-2.00%) | -500.00K |
Net Interest Income | 740K (-32.11%) | 1.09M (+3.81%) | 1.05M (+15.38%) | 910K (+26.39%) | 720K (+28.57%) | 560K (+1.82%) | 550K (-1.79%) | 560K (0.00%) | 560K (-1.75%) | 570K (+3.64%) | 550K |
Other Non Operating Income | -190.00K | - | 1.29M (+2050.00%) | 60K (0.00%) | 60K (+20.00%) | 50K (+400.00%) | 10K (-66.67%) | 30K (0.00%) | 30K | - | -640.00K |
Net Income | |||||||||||
Income Before Tax | -7.51M (+1.76%) | -7.38M (+10.48%) | -6.68M (-22.95%) | -8.67M (-39.58%) | -14.35M (+3.54%) | -13.86M (-21.87%) | -17.74M (-12.00%) | -20.16M (-1.37%) | -20.44M (+7.75%) | -18.97M (+24.88%) | -15.19M |
Net Income From Continuing Operations | -7.51M (+1.76%) | -7.38M (+10.48%) | -6.68M (-22.95%) | -8.67M (-39.58%) | -14.35M (+3.54%) | -13.86M (-21.87%) | -17.74M (-12.00%) | -20.16M (-1.37%) | -20.44M (+7.75%) | -18.97M (+24.88%) | -15.19M |
Net Income | -7.51M (+1.76%) | -7.38M (+10.48%) | -6.68M (-22.95%) | -8.67M (-39.58%) | -14.35M (+3.54%) | -13.86M (-21.87%) | -17.74M (-12.00%) | -20.16M (-1.37%) | -20.44M (+7.75%) | -18.97M (+24.88%) | -15.19M |